Shorter all-oral treatment for Rifampicin-resistant TB
Part of Infections, Lungs & breathing clinical trials.
This study tests a shorter, all-oral treatment for people with Rifampicin-resistant TB. It aims to see if a new combination of drugs works well and safely over a shorter time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old and weigh at least 30 kg (66 lbs).
- You must have TB that is resistant to Rifampicin but still sensitive to either Moxifloxacin or Levofloxacin.
- Your TB must be confirmed by a positive sputum or airway fluid culture within the last 3 months.
- You cannot have been treated with Bedaquiline or Linezolid for more than 30 days before this study.
- You must not have serious heart, kidney, liver, or nerve problems that could worsen during the trial.
- Women must not be pregnant or breastfeeding and must use birth control; men must use condoms or other effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a shorter, all-pill (oral) treatment plan for people with rifampicin-resistant pulmonary tuberculosis. It aims to improve treatment while reducing the burden of therapy, using a plan tailored to the individual.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This study is testing whether a shorter course of TB medicine works just as well as the standard longer treatment for children with drug-susceptible tuberculosis. It aims to make treatment easier for families.
This trial tests a shorter treatment regimen for people with tuberculosis (TB) who don't have symptoms. If you have TB bacteria in your lungs but no cough, fever, night sweats, or weight loss, this study may offer a more convenient treatment option.
This trial tests a 6-month treatment for people with rifampicin-resistant tuberculosis (TB). It aims to see if a shorter, simpler regimen works as well as longer treatments. You may qualify if you have this type of TB and meet a few health requirements.
This study tests a very short treatment for active lung TB in people aged 65 and older. The goal is to see if a short course of medicines can effectively cure TB without side effects.
Hear when a new Rifampicin-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.